Nymox Pharmaceutical Corp (NASDAQ:NYMX)

CAPS Rating: 1 out of 5

A biopharmaceutical company with three proprietary products on the market and a R&D of drug & diagnostic products in development for the treatment of enlarged prostate, Alzheimer's disease contamination of food and drink products and bacterial infections.

Caps

How do you think NYMX will perform against the market?

Add Stock to CAPS Watchlist

All Players

63 Outperform
60 Underperform
 

All-Star Players

9 Outperform
31 Underperform
 

Wall Street

0 Outperform
1 Underperform
 

Top NYMX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

mshakin1 (< 20)
Submitted May 27, 2010

The NYMOX drug for BPH, NX1207, is head and shoulders above all the existing drugs for this ailment, which affects tens of millions of middle age and elderly men. Not only is NX1207 so much more effective than Flomax and Avodart is decreasing BPH,… More

zzlangerhans (99.86)
Submitted March 25, 2015

As far as biopharma stocks go, they don't get much worse than the Canadian scam Nymox. Despite the predictable failure of the phase III trials of NX03-0040 for BPH which dropped the stock as low as 0.36, Nymox has been caught up in the wave of… More

NYMX VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about NYMX.

Recs

0
Member Avatar TerryHogan (99.97) Submitted: 10/25/2018 12:54:53 AM : Underperform Start Price: $1.58 NYMX Score: -27.22

The best I can say about this stock is that the cash burn rate is pretty low in terms of actual dollars. But only real source of cash is share issuance. I have serious 'going concern' issues about this stock.

Recs

0
Member Avatar Bigsef77 (68.70) Submitted: 10/3/2018 1:22:56 PM : Outperform Start Price: $1.47 NYMX Score: +10.06

Nymox Reports Safety Benefits of Fexapotide Treatments for Prostate Cancer and Benign Prostatic Hyperplasia
GlobeNewswire•October 3, 2018

HASBROUCK HEIGHTS, N.J., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NYMX) reported today that after long-term safety assessments of repeated Fexapotide Triflutate (FT) intraprostatic injections, there have been no identifiable risks or serious side effects or adverse events identified associated or linked with the drug.

FT is Nymox's lead drug for which the Company is in the process of seeking U.S. and European marketing approvals for BPH (prostate enlargement), and FT is also in late stage development for prostate cancer. Pivotal trial results for FT BPH studies involving 977 treated patients were published in 2018 in the prestigious World Journal of Urology (May 2018, Volume 36, pages 801–809), and the safety and efficacy results have been presented to the American Urology Association and previously to the European Association of Urology.

Dr. Paul Averback, CEO of Nymox said, "For prostate cancer in particular, repeated injection treatments will be needed and a focal molecular treatment will have negligible value if there cannot be reliable safety expected from repeated injection. Prostate cancer is a multi-focal disease and it is to be expected that multiple focal molecular treatments will be utilized for optimal outcomes. Follow-up and re-treatment will be needed. Nymox undertook 2 large FT re-injection safety studies in 2010-2014 involving 351 subjects with BPH, who were subsequently followed for up to 7 years. These mandatory and adequately sized safety studies are absolutely required in order to demonstrate safety of re-injection, and this is a standard requirement."

Dr Averback added, "In addition, Nymox undertook extensive immunological testing involving over 1000 subject samples, demonstrating that FT does not lead to detectable antibody formation, which underlines FT safety and supports the lack of risk for allergic reactions. All laboratory testing and sexual function tests including semen analyses showed no changes in FT treated men compared to controls."

Nymox's lead drug Fexapotide (FT) has been in development for over 10 years and has been tested by expert clinical trial investigative teams in over 70 distinguished clinical trial centers throughout the US, and has been found after 7 years of prospective placebo controlled double blind studies of treatment of 977 U.S. men with prostate enlargement to not only show clinically meaningful and durable relief of BPH symptoms, but also to show a major reduction in the incidence of prostate cancer, compared to placebo and compared to the known and expected normal incidence of the disease. The same clinical program has also shown in a long-term blinded placebo group study an 82-95% reduction in the number of these patients who required surgery after they received FT in the trial, as compared to patients who did not receive FT but instead later received conventional approved BPH treatments (p<.0001).

Recs

0
Member Avatar superstar2 (99.52) Submitted: 9/13/2016 12:15:20 PM : Outperform Start Price: $3.69 NYMX Score: -71.73

Impressive stage3 trial results on lead drug Fexapotide.

Leaderboard

Find the members with the highest scoring picks in NYMX.

Score Leader

BravoBevo

BravoBevo (99.96) Score: +397.02

God never does anything to cover a deficiency because He has none. Instead, everything that God does is to display His sufficiency, which is infinite. The chief end of God (and also should be of man) is to glorify God and to enjoy God forever.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
BetapegAnalytics < 20 8/18/2009 Underperform 5Y $4.51 -54.99% +176.09% +231.08 0 Comment
BicaChica 80.21 10/12/2009 Underperform 5Y $4.66 -56.44% +151.24% +207.68 0 Comment
RUMBLINstrflame < 20 12/2/2009 Underperform 5Y $4.52 -55.09% +143.30% +198.38 0 Comment
longtermgrowth09 < 20 12/17/2009 Underperform 5Y $4.27 -52.46% +144.53% +196.99 0 Comment
roth450 29.05 7/23/2010 Underperform NS $3.80 -46.58% +147.84% +194.42 0 Comment
Okcfirefighter < 20 12/17/2010 Underperform 5Y $7.20 -71.81% +117.74% +189.55 0 Comment
boardwalken65 30.82 7/5/2011 Underperform 3M $8.24 -75.36% +102.38% +177.74 0 Comment
NetscribeHealthC 64.43 3/23/2007 Underperform 1Y $5.95 -65.88% +99.77% +165.65 1 Comment
Fastball07 70.49 11/20/2007 Underperform 3M $6.40 -68.28% +96.95% +165.23 0 Comment
flyboyl6 34.31 2/6/2007 Underperform NS $5.42 -62.55% +98.62% +161.16 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackBioLogicEqu < 20 2/15/2011 Underperform NS $6.49 -68.72% +103.53% +172.25 0 Comment

Advertisement